Is CytomX Therapeutics, Inc. overvalued or undervalued?

As of 3 September 2025, the valuation grade for CytomX Therapeutics, Inc. has moved from attractive to very attractive, indicating a significant improvement in its valuation outlook. The company appears to be undervalued, particularly given its P/E ratio of 10, which is favorable compared to the industry average, and a PEG ratio of 0.14, suggesting strong growth potential relative to its price. Additionally, the EV to EBITDA ratio stands at 9.07, further supporting the undervaluation thesis.
In comparison to its peers, CytomX Therapeutics shows a much lower P/E ratio than Chimerix, Inc. at -8.6897 and a more favorable EV to EBITDA than Aquestive Therapeutics, Inc. at -12.8252, highlighting its relative strength in valuation metrics. While the stock has experienced a YTD return of 98.06% compared to the S&P 500's 12.22%, it has struggled in the longer term, with a 5Y return of -72.43% versus the S&P 500's 96.61%. This contrast in performance underscores the potential for recovery and growth in the coming periods.